0
     

Report Added
Report already added
Bacterial Vaginosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Bacterial Vaginosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Vaginosis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Bacterial Vaginosis (Infectious Disease) pipeline landscape.

Bacterial vaginosis (BV), also known as vaginal bacteriosis is a type of vaginal inflammation caused by overgrowth of bacteria present in vagina. Symptoms include vaginal itching; burning during urination and vaginal discharge may become watery and thin. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bacterial Vaginosis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Bacterial Vaginosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacterial Vaginosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Vaginosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 6, 3, 8, 2 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Bacterial Vaginosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Vaginosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Bacterial Vaginosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bacterial Vaginosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bacterial Vaginosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Vaginosis (Infectious Disease)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bacterial Vaginosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bacterial Vaginosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bacterial Vaginosis - Overview
Bacterial Vaginosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Bacterial Vaginosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bacterial Vaginosis - Companies Involved in Therapeutics Development
AtoGen Co Ltd
BioNTech SE
Evofem Biosciences Inc
Ferring Pharmaceuticals Inc
Guangdong Longchuangji Pharmaceutical Co Ltd
Hammock Pharmaceuticals Inc
Hennepin Life Sciences LLC
Melinta Therapeutics Inc
Mucommune LLC
MyBiotics Pharma Ltd
Next Science Ltd
Osel Inc
Pharmiva AB
Profem GmbH
Seed Health Inc
Sichuan Anaerobic Biotechnology Co Ltd
Starpharma Holdings Ltd
Suzhou Kanger Biomedical Co Ltd
Suzhou Ousai Weike Biomedical Technology Co Ltd
TenNor Therapeutics Ltd
Toltec Pharmaceuticals LLC
Zhejiang Xinlifei Biotechnology Co Ltd
Bacterial Vaginosis - Drug Profiles
(citric acid + lactic acid + potassium bitartrate) - Drug Profile
Product Description
Mechanism Of Action
History of Events
astodrimer - Drug Profile
Product Description
Mechanism Of Action
History of Events
Biologic for Bacterial Vaginosis - Drug Profile
Product Description
Mechanism Of Action
Biologic for Bacterial Vaginosis - Drug Profile
Product Description
Mechanism Of Action
Biologics for Bacterial Vaginosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drug for Bacterial Vaginosis - Drug Profile
Product Description
Mechanism Of Action
Golden Ring Snake Antibacterial Peptide - Drug Profile
Product Description
Mechanism Of Action
KAL-001 - Drug Profile
Product Description
Mechanism Of Action
LABthera-001 - Drug Profile
Product Description
Mechanism Of Action
lactic acid SR - Drug Profile
Product Description
Mechanism Of Action
History of Events
LACTIN-V - Drug Profile
Product Description
Mechanism Of Action
History of Events
Lactobacillus dual live bacteria - Drug Profile
Product Description
Mechanism Of Action
MBXSD-103 - Drug Profile
Product Description
Mechanism Of Action
metronidazole - Drug Profile
Product Description
Mechanism Of Action
History of Events
P-001 - Drug Profile
Product Description
Mechanism Of Action
PM-477 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Prof-002 - Drug Profile
Product Description
Mechanism Of Action
radezolid - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile
Product Description
Mechanism Of Action
subtilosin - Drug Profile
Product Description
Mechanism Of Action
TNP-2198 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TOL-463 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VMSC-015 - Drug Profile
Product Description
Mechanism Of Action
Bacterial Vaginosis - Dormant Projects
Bacterial Vaginosis - Discontinued Products
Bacterial Vaginosis - Product Development Milestones
Featured News & Press Releases
Sep 25, 2020: VivaGel BV secures TGA approval for prevention of BV
Jun 16, 2020: VivaGel BV launched in central and eastern European countries
May 13, 2020: Osel’s live biotherapeutic product demonstrates efficacy in phase 2b study of bacterial vaginosis
Nov 13, 2019: Starpharma announces UK launch of VivaGel BV
Sep 28, 2019: Congratulations to Guangdong Longchuangji Pharmaceutical a subsidiary of Qiangji Pharmaceutical, for obtaining clinical approval for the "Vaginal Lactobacillus Double Live Capsules" developed
Sep 03, 2019: VivaGel BV regulatory approvals continue in Asia
Aug 15, 2019: First Asian regulatory approvals received for VivaGel BV
Apr 16, 2019: First VivaGel BV launch globally in Australia by Aspen
Sep 21, 2018: New Data on Patient Acceptability and Genitourinary Effects of Evofem Biosciences' Amphora and its Role as a Multipurpose Vaginal pH Regulator (MVP-R) to be Presented at the 2018 American Society For Reproductive Medicine Annual Congress
Jul 09, 2018: VivaGel BV NDA advances to next stage of FDA review
Apr 30, 2018: Starpharma completes US New Drug Application for VivaGel BV
Jan 18, 2018: Melinta Therapeutics Announces Initiation of Program for Radezolid in Patients with Bacterial Vaginosis
Jan 17, 2018: Osel’s LACTIN-V Enters Clinical Study to Improve the Success Rate of IVF in Women With Imbalanced Vaginal Microbiomes
Nov 21, 2017: Starpharma: NDA submission for VivaGel BV in the US
Oct 25, 2017: VivaGel BV granted marketing approval in Australia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Bacterial Vaginosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Bacterial Vaginosis - Pipeline by AtoGen Co Ltd, 2022
Bacterial Vaginosis - Pipeline by BioNTech SE, 2022
Bacterial Vaginosis - Pipeline by Evofem Biosciences Inc, 2022
Bacterial Vaginosis - Pipeline by Ferring Pharmaceuticals Inc, 2022
Bacterial Vaginosis - Pipeline by Guangdong Longchuangji Pharmaceutical Co Ltd, 2022
Bacterial Vaginosis - Pipeline by Hammock Pharmaceuticals Inc, 2022
Bacterial Vaginosis - Pipeline by Hennepin Life Sciences LLC, 2022
Bacterial Vaginosis - Pipeline by Melinta Therapeutics Inc, 2022
Bacterial Vaginosis - Pipeline by Mucommune LLC, 2022
Bacterial Vaginosis - Pipeline by MyBiotics Pharma Ltd, 2022
Bacterial Vaginosis - Pipeline by Next Science Ltd, 2022
Bacterial Vaginosis - Pipeline by Osel Inc, 2022
Bacterial Vaginosis - Pipeline by Pharmiva AB, 2022
Bacterial Vaginosis - Pipeline by Profem GmbH, 2022
Bacterial Vaginosis - Pipeline by Seed Health Inc, 2022
Bacterial Vaginosis - Pipeline by Sichuan Anaerobic Biotechnology Co Ltd, 2022
Bacterial Vaginosis - Pipeline by Starpharma Holdings Ltd, 2022
Bacterial Vaginosis - Pipeline by Suzhou Kanger Biomedical Co Ltd, 2022
Bacterial Vaginosis - Pipeline by Suzhou Ousai Weike Biomedical Technology Co Ltd, 2022
Bacterial Vaginosis - Pipeline by TenNor Therapeutics Ltd, 2022
Bacterial Vaginosis - Pipeline by Toltec Pharmaceuticals LLC, 2022
Bacterial Vaginosis - Pipeline by Zhejiang Xinlifei Biotechnology Co Ltd, 2022
Bacterial Vaginosis - Dormant Projects, 2022
Bacterial Vaginosis - Discontinued Products, 2022

List of Figures
Number of Products under Development for Bacterial Vaginosis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Report Title: Bacterial Vaginosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Dental Imaging Systems: Global Markets

Dental Imaging Systems: Global Markets

Telecom operators’ strategies in the health market

Telecom operators’ strategies in the health market

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline